The goal of this Phase II SBIR is to convert Profusa?s bulky, cabled, optical reader into a wearable, flexible, disposable, bandage-like format that conforms to the foot for continuous monitoring of tissue oxygen levels during revascularization and restenosis in patients with peripheral artery disease. PAD is a manifestation of systemic atherosclerosis that affects 10-12 million people in the U.S., with prevalence increasing with age. PAD ranges from mild (accompanied by intermittent claudication or pain with exercise) to severe (accompanied by CLI and gangrene), and is associated with high rates of amputation, mortality and poor quality of life. With the appropriate monitoring and treatment, disease progression can be halted and even reversed, but easy-to-use, accurate monitoring products to indicate when a change in therapy is needed do not exist. A tissue oxygen-monitoring tool that is minimally invasive, offers high sensitivity and stability, and could give rapid tissue measurements, would be ideal for point-of-care monitoring and remote continuous measurements. PROFUSA?s oxygen sensing technology can help salvage limbs from amputation by providing a way to measure real-time tissue oxygen levels in the ischemic limb before, during, and after treatment, thus enabling appropriate therapy to be administered in a timely fashion before advanced symptoms appear. The development of the flexible patch reader would allow for continuous wireless monitoring, giving critical patient data to doctors, patients, or other caregivers in real-time. Furthermore, this technology has the potential to be transformative, not just for PAD, but for the broad field of continuous in vivo diagnostics and mobile health monitoring. In this Phase II SBIR grant, we propose to first convert Profusa?s current optical reader into a flexible, wearable format (i.e. optical patch reader) through component redesign using novel flexible, thin-film, conformal electronics. We will then test the redesigned flexible patch reader in vitro. Lastly, the project will culminate in a clinical study to test safety, wearability (human factors) and in vivo functionality.

Public Health Relevance

Peripheral arterial disease (PAD), in which plaque buildup obstructs arteries causing decreased tissue oxygen levels, is estimated to affect 10 to 12 million people in the U.S., creating an annual economic burden of more than $74B. Decreased tissue oxygen levels can lead to intermittent claudication or, in more advanced cases, gangrene and amputation. Development of a flexible patch reader as a companion device to Profusa?s oxygen sensing technology would allow for continuous wireless monitoring which could help salvage limbs from amputation by providing a way to measure real-time tissue oxygen levels in the ischemic limb before, during, and after treatment, thus enabling appropriate therapy to be administered in a timely fashion before advanced symptoms appear.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44HL134532-02
Application #
9345576
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Reid, Diane M
Project Start
2016-09-03
Project End
2019-06-30
Budget Start
2017-07-01
Budget End
2019-06-30
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Profusa, Inc.
Department
Type
DUNS #
830219338
City
South San Francisco
State
CA
Country
United States
Zip Code
94080
Nichols, Scott P; Balaconis, Mary K; Gant, Rebecca M et al. (2018) Long-Term In Vivo Oxygen Sensors for Peripheral Artery Disease Monitoring. Adv Exp Med Biol 1072:351-356